This indicator reflects the proportion of women who experienced a live birth within the last two years and received
adequate preventive treatment against malaria during their pregnancy, specifically focusing on those who consumed Sulfadoxine-Pyrimethamine (SP/Fansidar) in two or more doses. High levels of adherence to this protocol are crucial for safeguarding maternal and fetal health, as malaria poses significant risks in pregnancy, including severe anemia and increased mortality. The data highlights disparities in access to effective malaria prevention strategies among expectant mothers, illuminating areas for potential improvement in healthcare delivery and awareness. Moreover, by tracking this usage, public health initiatives can better assess the impact of existing interventions and ensure better health outcomes for both mothers and their newborns in malaria-endemic regions.
Source: